GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (FRA:REG) » Definitions » EV-to-EBITDA

RemeGen Co (FRA:REG) EV-to-EBITDA : -13.65 (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is RemeGen Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, RemeGen Co's enterprise value is €2,219.1 Mil. RemeGen Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €-162.5 Mil. Therefore, RemeGen Co's EV-to-EBITDA for today is -13.65.

The historical rank and industry rank for RemeGen Co's EV-to-EBITDA or its related term are showing as below:

FRA:REG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -291.57   Med: -17.2   Max: 72.87
Current: -13.6

During the past 6 years, the highest EV-to-EBITDA of RemeGen Co was 72.87. The lowest was -291.57. And the median was -17.20.

FRA:REG's EV-to-EBITDA is ranked worse than
100% of 445 companies
in the Biotechnology industry
Industry Median: 9.7 vs FRA:REG: -13.60

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-12), RemeGen Co's stock price is €2.02. RemeGen Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.379. Therefore, RemeGen Co's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


RemeGen Co EV-to-EBITDA Historical Data

The historical data trend for RemeGen Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co EV-to-EBITDA Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - -61.94 73.25 -32.66 -15.38

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.78 -32.66 -16.35 -15.38 -

Competitive Comparison of RemeGen Co's EV-to-EBITDA

For the Biotechnology subindustry, RemeGen Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RemeGen Co's EV-to-EBITDA falls into.



RemeGen Co EV-to-EBITDA Calculation

RemeGen Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2219.124/-162.538
=-13.65

RemeGen Co's current Enterprise Value is €2,219.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RemeGen Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €-162.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RemeGen Co  (FRA:REG) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

RemeGen Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.02/-0.379
=At Loss

RemeGen Co's share price for today is €2.02.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RemeGen Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.379.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


RemeGen Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of RemeGen Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.